I have been the supervisor of a comparable study programme, the DIMCA programma, from 1992 -2007. My department and study programme received funrestricted study grants from pharmaceutical industries for this and other research REVIEW RETURNED 04-Oct-2013
GENERAL COMMENTS
I would advice a statistical check, although to me this looks rather well thought-through.
Most aspects are covered, though I would like the paper to be more specific on a number of aspects. Insufficient to mark 'no' but important enough to mention. I have done that under 'further comments'.
This study protocol sets-out to establish the effects of early case finding and intervention with Tiotropium on pulmonary function and pulmonary function decline in patients with mild-moderate COPD. The study is most timely, given the high prevalence of COPD in China and the poor prognosis of COPD after its development. I have a couple of comments, to further improve this nice protocol: There have been earlier studies that looked in the effectiveness of intervening in the milder stages of COPD and most of these studies are referred to in the protocol. I would like to drew the authors" attention to the DIMCA study that took place in Dutch primary health care, in the early 1990-s and put a number of references in, below, for that purpose. The DIMCA study worked from a primary health care population screening, focussing on as yet undiagnosed and therefore not treated patients. This comes close to the rationale of this study that addresses the substantial under-treatment of COPD in China.
In the DIMCA study, treatment was inhaled corticosteroids and its effects were analysed separately for patients with mild symptoms, and patients with a rapid decline of pulmonary function [1, 2] . Effects were particularly in the domain of empowerment, quality of life and functioning, even though the pulmonary function as such was largely uninfluenced by the intervention [3, 4] . A problem encountered in the DIMCA study that might also play a role in this study is the difficulty to diagnose "early signs and symptoms" in diagnostic terms: even after 5 -10 years of systematic monitoring and follow-up, there was substantial variation in symptoms [5, 6] , it was not possible to define for each study participant if there was COPD or just chronic recurrent symptoms (results not published). Although this study sets-out to include patients with COPD Gold stages 1 and 2, it is quite possible that in a number of them at the inclusion stage no firm diagnosis can be made and the authors have to do so on the basis of the further study data. It would be good to have a ruling for this in the protocol: will this be done on the basis of study data vis a vis the GOLD criteria, or include as well an assessment by a chest physician? Where are patients recruited from: is it a population survey, or a recruitment from active patients" lists in practices and hospitals? Is it referral hospitals or community primary care practices? Most patients with GOLD 1, 2 COPD are treated (when diagnosed!) in the primary care setting. Inclusion of GOLD 1, 2 COPD from referral hospitals may decrease the external validity of the study findings as these patients could have been selectively referred due to other characteristics. More information should be given on the way smoking cessation id handled in this study. Stopping smoking is the most effective way of reducing the impact of COPD in terms of burden of symptoms and lung function decline. And although smoking cession is not part of the intervention, all study participants should be entitled to a stateof-the-art smoking cessation intervention. It can be assumed that the take-up rate of this would be comparable in intervention group and control group. But it is important that all participants receive this and that participation is monitored alongside actual smoking status during the course of the trial.
The treatment of COPD exacerbations should be specified, as adequate treatment might improve long-term outcome of COPD: do the treating physicians of the study participants receive an instruction and/or set of interventions, to make sure that exacerbations will be treated consistently according to current best practice. Monitoring of the adherence of treating physicians to this instruction would be important as well. 
This manuscript describes the design of a 2-year placebo-controlled, parallel-group randomized clinical trial of once-daily tiotropium vs. placebo in Chinese patients with early stage (GOLD I-II) COPD. As such, it fulfills a largely unmet need to determine the efficacy of early pharmacologic intervention in patients with early-stage COPD who are largely asymptomatic (or, at least, deny respiratory symptoms).
Some questions regarding the design of the study need to be addressed more fully.
For example, it is not entirely clear whether smoking (or how much smoking, e.g., in pack-yrs) is an eligibility requirement.
For smokers enrolled in this trial, clearly an effort should be made to motivate the patients to quit smoking. Therefore, the authors should describe the methods that they will employ in an attempt to achieve this objective. Also, the analysis will need to take into account the smoking status of the patients and any changes in this status over the course of the trial.
Since most of the subjects will likely be asymptomatic (or, at least, deny symptoms), how will recruitment be conducted? A previous study of early intervention in COPD, namely the Lung Health Study, used a large-scale spirometry screening approach targeted to smokers (with or without symptoms consistent with COPD); in that study approximately 10 times as many smokers were screened as those who were identified as having spirometric evidence of COPD (based on a post-bronchodilator FEV1/FVC < 0.70). Will as similar approach be used in this study? Since a minority of COPD patients do not have a smoking history, will such non-smokers be included or excluded? In the Lung Health Study, subjects with a reduced FEV1/FVC ratio who had a post-bronchodilator FEV1 >90% were excluded. Will such patients be included or excluded in the current study?
Since a large proportion, if not most, of the participants with earlystage COPD who are enrolled into this study are likely to be asymptomatic, the likelihood of non-adherence is strong. How will this be assessed and, if non-adherence is found, how will it be handled?
In their study design, the authors state that patients with GOLD I an II will be randomized. However, since a large number of patients with GOLD II have already been represented in a subgroup analysis of the UPLIFT trial (N=2379) (Decramer et al., 2009) , including 1210 patients with a post-bronchodilator FEV160% predicted (Tashkin et al. COPD 2012; 9:2890-96) , have the authors considered focusing largely on patients with GOLD I and the upper range of GOLD II (i.e., post-bronchodilator FEV1 70-80% predicted)?
The authors have specified the trough FEV1 at 2 years as the primary endpoint, presumably adjusting for the trough FEV1 at baseline. Since the ultimate objective of this study is to determine whether early-enough intervention at a stage of COPD characterized by the greatest rate of decline in FEV1 could modify the course of the disease, it is somewhat surprising that the rates of decline in post-and pre-bronchodilator FEV1 were not considered as coprimary endpoints (as in UPLIFT). Further details are required concerning the methods of statistical analysis, particularly for the rates of decline in lung function and the manner in which the impact of therapy on exacerbations of COPD is analyzed.
Since the participants in this trial are likely largely to be asymptomatic, the 35% discontinuation rate, as projected by the authors, might be an under-estimate, if one considers nonadherence to be a relatively common reason for premature discontinuation from the study.
Finally, in view of the change in the classification of the severity of COPD by GOLD according to composite of symptoms and risk (including exacerbation frequency), the authors might consider describing their patients in accordance with the new classification (i.e., as GOLD Grade A or B). This said, I still feel that an emphasis should be placed on recruiting subjects with lesser degrees of airflow obstruction (i.e., post-bronchodilator over 70% predicted, along with a post-bronchodilator FEV1/FVC <0.70), since such patients have been markedly under-represented in previous trials.
SPECIFIC COMMENTS:
Page 4, lines 6-9: Change "patients who use tiotropium as a first maintenance" to patients who had not received any maintenance medication for COPD before enrolling in UPLIFT" since not all of these patients will be randomized to receive tiotropium after they enter the trial.
Page 8, line 17: Since the peak effect of salbutamol on FEV1 occurs ~1 hr or more after the drug is administered, waiting only 20 minutes may result in a submaximal response to this bronchodilator. Replicating the strategy used in UPLIFT (post-bronchodilator spirometry 90 minutes after 4 inhalations of ipratropium and 60 minutes after salbutamol) would more likely yield a near-maximal response.
Page 10, line 34: Change "undertreatment" to "undertreated".
Page 11, line 21 or 22: Change "outcomes of COPD patients has improved" to "outcomes of COPD patients have improved". 
GENERAL COMMENTS
This is a comprehensive-executive summary of a RCT (nickname, Tie-COPD) already in progress, conducted in China and supported by a renowned international pharma industry related to the production, marketing and distribution of tiotropium, one of the most potent LAMAs. That said let me make a few comments and criticisms COMMENT 1) The idea has been speculated/elabrorated for a long time in different forums in which the main target has been an early intervention in COPD. Yet, in this RCT there is a matter of concern. This refers to the presence/absence of respiratory symptoms, as they are not referred in the inclusion criteria. This challenges seriously the concept of the current COPD international recommendations that indicate that bronchodilators should be given only in the presence of symptoms. And, then, the other major concern is that there is no alternative option given to the participants who still are current smokers. One would expect that, at least, a three months period should be offer to each of them and then, if this fails, be recruited for the study. In my opinion, this omission raises some ethical concerns in the design of this RCT. Moreover, nothing is said in teh Discussion in regards to what happens with the persistence of smoking.
OTHER COMMENTS
2) Smoking habits and criteria should be explained more in detail.
3) There is no mention of frequent exacerbators. According to the Hurst J et al."s NEJM paper, up to 22% of patients in GOLD grade 2 can be considered frequent exacerbators. A few words should be devoted to this COPD phenotype. 4) Pg 9, Para-1, Ls 1-5: Severity of exacerbations essentially follows an event-driven exactly defined as such in Chest 2000; 117(Suppl 2): 398S-401S. I suggest including this reference. 5) In the same Pg 9, Para-3, please quote where the 35% patient drop-out rate is taken from. 6) In Pg 11, Para-3, L 6, a more recent paper on the small airways-VQ abnormalities interaction should be taken into consideration (J Appl Physiol 2009; 106:1902 -1908 This type of papers has been published before with other famous RCTs, such as TORCH or UpLIFT, in respiratory journals like the ERJ. In this regard, there is not too say as far as the Referee is concerned. Indeed, to revise this paper is in part useless, since either the Editor decides to accept it or reject it. The content therefore has to be accepted as it is. So, I click 'Accept' but with the understanding that this an exclusive prerrogative of the Editor in Chief. This study protocol sets-out to establish the effects of early case finding and intervention with Tiotropium on pulmonary function and pulmonary function decline in patients with mild-moderate COPD. The study is most timely, given the high prevalence of COPD in China and the poor prognosis of COPD after its development. I have a couple of comments, to further improve this nice protocol: There have been earlier studies that looked in the effectiveness of intervening in the milder stages of COPD and most of these studies are referred to in the protocol. I would like to drew the authors" attention to the DIMCA study that took place in Dutch primary health care, in the early 1990-s and put a number of references in, below, for that purpose. The DIMCA study worked from a primary health care population screening, focussing on as yet undiagnosed and therefore not treated patients. This comes close to the rationale of this study that addresses the substantial under-treatment of COPD in China.
VERSION 1 -AUTHOR RESPONSE
In the DIMCA study, treatment was inhaled corticosteroids and its effects were analysed separately for patients with mild symptoms, and patients with a rapid decline of pulmonary function [1, 2] . Effects were particularly in the domain of empowerment, quality of life and functioning, even though the pulmonary function as such was largely uninfluenced by the intervention [3, 4] . A problem encountered in the DIMCA study that might also play a role in this study is the difficulty to diagnose "early signs and symptoms" in diagnostic terms: even after 5 -10 years of systematic monitoring and follow-up, there was substantial variation in symptoms [5, 6] , it was not possible to define for each study participant if there was COPD or just chronic recurrent symptoms (results not published). Although this study sets-out to include patients with COPD Gold stages 1 and 2, it is quite possible that in a number of them at the inclusion stage no firm diagnosis can be made and the authors have to do so on the basis of the further study data. It would be good to have a ruling for this in the protocol: will this be done on the basis of study data vis a vis the GOLD criteria, or include as well an assessment by a chest physician? RESPONSE: We thank the reviewer for these thoughtful comments. We agree with your comments. The DIMCA study is an excellent trial based on population survey. It showed that early intervention with fluticasone in subjects with objective signs of obstructive airway disease resulted in significant health gains at relatively low financial cost. So, there may also be beneficial effect if the patients receive routine treatment at an earlier stage of the disease. As the symptoms of patients with earlystage COPD are various, the diagnose of patients enrolled in our study were based on spirometry criteria of GOLD, regardless of the symptoms. The first spirometry was conducted in the population survey and then they were recruited to the hospital to confirm the diagnose after 2-3 months.
Where are patients recruited from: is it a population survey, or a recruitment from active patients" lists in practices and hospitals? Is it referral hospitals or community primary care practices? Most patients with GOLD 1, 2 COPD are treated (when diagnosed!) in the primary care setting. Inclusion of GOLD 1, 2 COPD from referral hospitals may decrease the external validity of the study findings as these patients could have been selectively referred due to other characteristics.
RESPONSE: The DIMCA study discovered that the mere presence of respiratory symptoms or a gradually reduced lung function is insufficient reason for patients to seek medical help. So, before the recruitment, we conducted a population screening for COPD through spirometry in community. Most of the patients enrolled in our study came from the population screening in community. After the survey, patients who satisfied the eligibility criteria were recruited. According to Hurst J, up to 22% of patients in GOLD stageⅡcan be considered frequent exacerbations. They may not at present be identified for interventions to reduce exacerbations and may get more benefit from the intervention. So, Some moderate COPD patients with history of exacerbations from hospital also were enrolled.
More information should be given on the way smoking cessation id handled in this study. Stopping smoking is the most effective way of reducing the impact of COPD in terms of burden of symptoms and lung function decline. And although smoking cession is not part of the intervention, all study participants should be entitled to a state-of-the-art smoking cessation intervention. It can be assumed that the take-up rate of this would be comparable in intervention group and control group. But it is important that all participants receive this and that participation is monitored alongside actual smoking status during the course of the trial.
RESPONSE: Smoking cessation is an effective intervention for COPD. Because most patients came from population screening in community, active smokers had been advised to discontinue smoking and offered a smoking cessation program as counseling sessions, patient education and supportive literature in the survey. After the survey, usually 2-3months, COPD patients at GOLD stages I and II were informed about the study and the benefit of smoking cessation again. In order to avoid the confounding effects of smoking cessation, we will not provide special smoking cessation intervention. Self-reported smoking status is recorded at each visit. When the trial is ended, we will consider the impact of smoking by statistical analysis. We have added the information about smoking cessation intervention in the part of Recruitment and Discussion on page 8 and 18.
The treatment of COPD exacerbations should be specified, as adequate treatment might improve long-term outcome of COPD: do the treating physicians of the study participants receive an instruction and/or set of interventions, to make sure that exacerbations will be treated consistently according to current best practice. Monitoring of the adherence of treating physicians to this instruction would be important as well.
RESPONSE: Thank you for your good suggestion. We complement the information of quality control on page 12. Before the recruitment, the principal investigator should ensure adequate training and updated information or notifications have been delivered to study relevant personnels including physicians and nurses. The principal investigator at each site is responsible for the inspection of the compliance to the protocol in terms of study conduction, accurate and timely data documentation in the CRF by investigators. The investigator/institution will permit trial-related monitoring, auditing, IRB / IEC review and regulatory inspection and will be providing relevant inspectors with direct access to all related source data/documents. This manuscript describes the design of a clinical trial for which there clearly is an unmet need, namely, to determine the utility of maintenance treatment of largely asymptomatic, early-stage COPD with maintenance pharmacotherapy, in this case, tiotropium. Aside from the question of the policy of BMJopen regarding publication of study design papers, I have a number of questions and concerns that need to be addressed, as stated in my comments to the authors, before the paper is considered for publication.
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GENERAL COMMENTS:
RESPONSE: Smoking status is not an eligibility requirement. That is to say the patients were recruited regardless of the smoking status. We have added it in the eligibility criteria on page 8.
RESPONSE: Active smokers were advised to discontinue smoking and offered a smoking cessation program as counseling sessions, patient education and supportive literature in a population survey before recruited. After the survey, usually 2-3months, COPD patients with GOLD stages I and II were recruited and informed of the study and the benefit of smoking cessation again. In order to avoid the confounding effects of smoking cessation, we will not provide special smoking cessation intervention. Self-reported smoking status is recorded at each visit. When the trial is ended, we will consider the impact of smoking by statistical analysis. We have added the information about smoking cessation intervention in the part of Recruitment and Discussion on page 8 and 18.
Since most of the subjects will likely be asymptomatic (or, at least, deny symptoms), how will recruitment be conducted? A previous study of early intervention in COPD, namely the Lung Health Study, used a large-scale spirometry screening approach targeted to smokers (with or without symptoms consistent with COPD); in that study approximately 10 times as many smokers were screened as those who were identified as having spirometric evidence of COPD (based on a postbronchodilator FEV1/FVC < 0.70). Will as similar approach be used in this study? Since a minority of COPD patients do not have a smoking history, will such non-smokers be included or excluded? In the Lung Health Study, subjects with a reduced FEV1/FVC ratio who had a post-bronchodilator FEV1 >90% were excluded. Will such patients be included or excluded in the current study? RESPONSE: Most of the patients came from population screening for COPD in community. After the survey, patients who satisfied the eligibility criteria (post-bronchodilator FEV1/FVC < 0.70，and FEV1≥50% predicted) were recruited. Some moderate COPD patients with history of exacerbations from hospital were also enrolled. Smoking status is not an eligibility requirement. Subjects with a reduced FEV1/FVC ratio who had a post-bronchodilator FEV1 >90% were also included.
Since a large proportion, if not most, of the participants with early-stage COPD who are enrolled into this study are likely to be asymptomatic, the likelihood of non-adherence is strong. How will this be assessed and, if non-adherence is found, how will it be handled? RESPONSE: We completely agree with you. Compliance is a matter of great concern. In order to reduce the drop-out rate, we will conduct scheduled health education for patients, including smoking cessation, benefit of early intervention, health consultation, etc. Meanwhile,we will establish a good relationship with the participants, and supervise them through unscheduled telephone follow-up. The quantity of retrieved investigational drug (capsules) should be recorded in the case report form. Administration of 80%-120% of the predicted use of investigational drug will be considered to be good compliance. The researchers will review patients" diary together with the patients to ensure the use of drugs. We will decide whether patients should be withdrawn from the trial according to the patients" compliance.
In their study design, the authors state that patients with GOLD I an II will be randomized. However, since a large number of patients with GOLD II have already been represented in a subgroup analysis of the UPLIFT trial (N=2379) (Decramer et al., 2009) , including 1210 patients with a postbronchodilator FEV1≥60% predicted (Tashkin et al. COPD 2012; 9:2890-96) , have the authors considered focusing largely on patients with GOLD I and the upper range of GOLD II (i.e., postbronchodilator FEV1 70-80% predicted)?
RESPONSE: Thank you for your helpful suggestion. At present, one third of the subjects enrolled were patients with GOLD stage I. And the most of the patients with GOLD II recruited have a postbronchodilator over 60% predicted. However, in order to compare the efficacy of intervention between GOLD stage I and II, we recruited patients with GOLD stages I and II.
The authors have specified the trough FEV1 at 2 years as the primary endpoint, presumably adjusting for the trough FEV1 at baseline. Since the ultimate objective of this study is to determine whether early-enough intervention at a stage of COPD characterized by the greatest rate of decline in FEV1 could modify the course of the disease, it is somewhat surprising that the rates of decline in post-and pre-bronchodilator FEV1 were not considered as co-primary endpoints (as in UPLIFT). Further details are required concerning the methods of statistical analysis, particularly for the rates of decline in lung function and the manner in which the impact of therapy on exacerbations of COPD is analyzed.
RESPONSE: As what we stated in the "statistical methods", the sample size of this study was calculated based on the improvement of FEV1 among GOLD stage II patients. We need a much larger sample size to detect decline rate improvement in FEV1 if we use it as a primary or co-primary endpoint in this study. Meanwhile, the investigators and the medical people from Boehringer Ingelheim were not confident enough to included decline rate of trough/peak FEV1 as a primary and put it as one of the secondary endpoints instead. At present, the recruitment has ended. It is difficult for the team of Tie-COPD to modify the primary endpoint. We have supply more information about statistical analysis on page 13-14.The analysis plan will be specified in detail in a separately prepared Statistical Analysis Plan (SAP) prior to database lock.
Since the participants in this trial are likely largely to be asymptomatic, the 35% discontinuation rate, as projected by the authors, might be an under-estimate, if one considers non-adherence to be a relatively common reason for premature discontinuation from the study.
RESPONSE: We completely agree with you. The discontinuation rate is a great challenge. We also have paid close attention to premature patient withdrawals. In order to reduce the dropout rate, we will conduct scheduled health education for patients, including smoking cessation, benefit of early intervention,health consulation, etc. Meanwhile, we will establish a good relationship with the participants, and supervise them through unscheduled telephone follow-up.
RESPONSE: We appreciate this suggestion and agree with you. It is more valuable to focus on the subjects with lesser degrees of airflow obstruction. Recruitment into the Tie-COPD trial started in November 2011 and ended in October 2013, with 839 patients randomized, one third of which are patients with GOLD stage I. The most of the patients with GOLD II recruited have a postbronchodilator over 60% predicted.
SPECIFIC COMMENTS:
RESPONSE: It has been changed.
